Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Moon, Hyeong Gon ^a   Yi, Jae K ^a   Kim, Hee S ^b   Lee, Hea Y ^a   Lee, Kyung Min ^a   Yi, Minju ^a   Ahn, Sookyung ^a   Shin, Hee Chul ^c   Ju, Ji hyun ^d   Shin, Incheol ^d   Han, Wonshik ^a   Noh, Dong Young ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Gachon University   (South Korea)

^c Chung Ang University College of Medicine   (South Korea)

^d Hanyang University   (South Korea)

Author keywords

Breast cancer; Chemotherapy; ERK; Estrogen receptor; P90RSK; Predictive marker

Indexed keywords

DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN; S6 KINASE; SMALL INTERFERING RNA;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; NEEDLE BIOPSY; PREDICTIVE VALUE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; HUMANS; MCF-7 CELLS; MIDDLE AGED; NEOADJUVANT THERAPY; PHOSPHORYLATION; RECEPTORS, ESTROGEN; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION; TAXOIDS;

EID: 84871105827     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-585     Document Type: Article

References (32)

1. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353(17):1784-1792. 10.1056/NEJMoa050518, 16251534.
2. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379(9814):432-444.
3. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(27):2817-2826. 10.1056/NEJMoa041588, 15591335.
4. McGlynn LM, Kirkegaard T, Edwards J, Tovey S, Cameron D, Twelves C, Bartlett JM, Cooke TG. Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. Clin Cancer Res 2009, 15(4):1487-1495. 10.1158/1078-0432.CCR-07-4967, 19228750.
5. Haagenson KK, Wu GS. The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev 2010, 29(1):143-149. 10.1007/s10555-010-9208-5, 20111893.
6. Small GW, Somasundaram S, Moore DT, Shi YY, Orlowski RZ. Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther 2003, 307(3):861-869. 10.1124/jpet.103.055806, 14557375.
7. Boutros T, Chevet E, Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev 2008, 60(3):261-310. 10.1124/pr.107.00106, 18922965.
8. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res 2005, 65(3):1027-1034.
9. Eisinger-Mathason TS, Andrade J, Lannigan DA. RSK in tumorigenesis: connections to steroid signaling. Steroids 2010, 75(3):191-202. 10.1016/j.steroids.2009.12.010, 2823981, 20045011.
10. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9(9):631-643. 10.1038/nrc2713, 19701242.
11. Esteva FJ, Hortobagyi GN. Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?. J Natl Cancer Inst 2008, 100(8):521-523. 10.1093/jnci/djn098, 18398093.
12. Moon HG, Han W, Noh DY. Comparable survival between pN0 breast cancer patients undergoing sentinel node biopsy and extensive axillary dissection: a report from the Korean Breast Cancer Society. J Clin Oncol 2010, 28(10):1692-1699. 10.1200/JCO.2009.25.9226, 20194848.
13. Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, Park IA, Noh DY, Chung JK, Bang YJ. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer 2011, 11:452. 10.1186/1471-2407-11-452, 3224348, 22011459.
14. Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG, et al. The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl) 2010, 4:35-41.
15. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10(6):515-527. 10.1016/j.ccr.2006.10.008, 2730521, 17157791.
16. Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, et al. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer 2007, 7:63. 10.1186/1471-2407-7-63, 1863427, 17430582.
17. Moon HG, Han W, Lee JW, Ko E, Kim EK, Yu JH, Kang SY, Moon WK, Cho N, Park IA, et al. Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol 2009, 20(4):636-641. 10.1093/annonc/mdn683, 19179551.
18. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008, 26(5):778-785. 10.1200/JCO.2007.15.0235, 18258986.
19. Romeo Y, Moreau J, Zindy PJ, Saba-El-Leil M, Lavoie G, Dandachi F, Baptissart M, Borden KL, Meloche S, Roux PP. RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth. Oncogene 2012, [Epub ahead of print].
20. Lucien F, Brochu-Gaudreau K, Arsenault D, Harper K, Dubois CM. Hypoxia-induced invadopodia formation involves activation of NHE-1 by the p90 ribosomal S6 kinase (p90RSK). PLoS One 2011, 6(12):e28851. 10.1371/journal.pone.0028851, 3246449, 22216126.
21. Ma Q, Guin S, Padhye SS, Zhou YQ, Zhang RW, Wang MH. Ribosomal protein S6 kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein. Mol Cancer 2011, 10:66. 10.1186/1476-4598-10-66, 3117816, 21619683.
22. Romeo Y, Roux PP. Paving the way for targeting RSK in cancer. Expert Opin Ther Targets 2011, 15(1):5-9. 10.1517/14728222.2010.531014, 20958120.
23. Stratford AL, Reipas K, Hu K, Fotovati A, Brough R, Frankum J, Takhar M, Watson P, Ashworth A, Lord CJ, et al. Targeting p90 Ribosomal S6 Kinase Eliminates Tumor-Initiating Cells by Inactivating Y-Box Binding Protein-1 in Triple-Negative Breast Cancers. Stem Cells 2012, 30(7):1338-1348. 10.1002/stem.1128, 22674792.
24. Xian W, Pappas L, Pandya D, Selfors LM, Derksen PW, de Bruin M, Gray NS, Jonkers J, Rosen JM, Brugge JS. Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Res 2009, 69(6):2244-2251. 10.1158/0008-5472.CAN-08-3398, 19258500.
25. Small GW, Shi YY, Higgins LS, Orlowski RZ. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 2007, 67(9):4459-4466. 10.1158/0008-5472.CAN-06-2644, 17483361.
26. Guise S, Braguer D, Carles G, Delacourte A, Briand C. Hyperphosphorylation of tau is mediated by ERK activation during anticancer drug-induced apoptosis in neuroblastoma cells. J Neurosci Res 2001, 63(3):257-267. 10.1002/1097-4547(20010201)63:3<257::AID-JNR1019>3.0.CO;2-T, 11170175.
27. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol 1998, 18(4):1978-1984. 121427, 9528769.
28. Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res 2005, 7(5):R753-764. 10.1186/bcr1285, 1242143, 16168121.
29. Jiang J, Sarwar N, Peston D, Kulinskaya E, Shousha S, Coombes RC, Ali S. Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin Cancer Res 2007, 13(19):5769-5776. 10.1158/1078-0432.CCR-07-0822, 17908967.
30. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13(8):2329-2334. 10.1158/1078-0432.CCR-06-1109, 17438091.
31. Moon HG, Im SA, Han W, Oh DY, Han SW, Keam B, Park IA, Chang JM, Moon WK, Cho N, et al. Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy: distinct patterns of response according to ER expression. Breast Cancer Res Treat 2012, 134(3):1133-1140. 10.1007/s10549-012-2145-y, 22752292.
32. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007, 25(28):4414-4422. 10.1200/JCO.2007.10.6823, 17785706.